Cargando…

Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model

New control methods are needed to counter antimicrobial resistances and the use of bacteriophages as an alternative treatment seems promising. To that end, the effect of the phage vB_KpnP_K1-ULIP33, whose host is the hypervirulent Klebsiella pneumoniae SA12 (ST23 and capsular type K1), was assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Laforêt, Fanny, Antoine, Céline, Lebrun, Sarah, Gonza, Irma, Goya-Jorge, Elizabeth, Douny, Caroline, Duprez, Jean-Noël, Scippo, Marie-Louise, Taminiau, Bernard, Daube, Georges, Fall, Abdoulaye, Thiry, Damien, Delcenserie, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057081/
https://www.ncbi.nlm.nih.gov/pubmed/36992428
http://dx.doi.org/10.3390/v15030719
_version_ 1785016275688226816
author Laforêt, Fanny
Antoine, Céline
Lebrun, Sarah
Gonza, Irma
Goya-Jorge, Elizabeth
Douny, Caroline
Duprez, Jean-Noël
Scippo, Marie-Louise
Taminiau, Bernard
Daube, Georges
Fall, Abdoulaye
Thiry, Damien
Delcenserie, Véronique
author_facet Laforêt, Fanny
Antoine, Céline
Lebrun, Sarah
Gonza, Irma
Goya-Jorge, Elizabeth
Douny, Caroline
Duprez, Jean-Noël
Scippo, Marie-Louise
Taminiau, Bernard
Daube, Georges
Fall, Abdoulaye
Thiry, Damien
Delcenserie, Véronique
author_sort Laforêt, Fanny
collection PubMed
description New control methods are needed to counter antimicrobial resistances and the use of bacteriophages as an alternative treatment seems promising. To that end, the effect of the phage vB_KpnP_K1-ULIP33, whose host is the hypervirulent Klebsiella pneumoniae SA12 (ST23 and capsular type K1), was assessed on intestinal microbiota, using an in vitro model: the SHIME(®) system (Simulator of the Human Intestinal Microbial Ecosystem). After stabilization of the system, the phage was inoculated for 7 days and its persistence in the different colons was studied until its disappearance from the system. The concentration of short chain fatty acids in the colons showed good colonization of the bioreactors by the microbiota and no significant effect related to the phage treatment. Diversity (α and β), the relative abundance of bacteria, and qPCR analysis targeting different genera of interest showed no significant variation following phage administration. Even if further in vitro studies are needed to assess the efficacy of this phage against its bacterial host within the human intestinal ecosystem, the phage ULIP33 exerted no significant change on the global colonic microbiota.
format Online
Article
Text
id pubmed-10057081
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100570812023-03-30 Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model Laforêt, Fanny Antoine, Céline Lebrun, Sarah Gonza, Irma Goya-Jorge, Elizabeth Douny, Caroline Duprez, Jean-Noël Scippo, Marie-Louise Taminiau, Bernard Daube, Georges Fall, Abdoulaye Thiry, Damien Delcenserie, Véronique Viruses Article New control methods are needed to counter antimicrobial resistances and the use of bacteriophages as an alternative treatment seems promising. To that end, the effect of the phage vB_KpnP_K1-ULIP33, whose host is the hypervirulent Klebsiella pneumoniae SA12 (ST23 and capsular type K1), was assessed on intestinal microbiota, using an in vitro model: the SHIME(®) system (Simulator of the Human Intestinal Microbial Ecosystem). After stabilization of the system, the phage was inoculated for 7 days and its persistence in the different colons was studied until its disappearance from the system. The concentration of short chain fatty acids in the colons showed good colonization of the bioreactors by the microbiota and no significant effect related to the phage treatment. Diversity (α and β), the relative abundance of bacteria, and qPCR analysis targeting different genera of interest showed no significant variation following phage administration. Even if further in vitro studies are needed to assess the efficacy of this phage against its bacterial host within the human intestinal ecosystem, the phage ULIP33 exerted no significant change on the global colonic microbiota. MDPI 2023-03-10 /pmc/articles/PMC10057081/ /pubmed/36992428 http://dx.doi.org/10.3390/v15030719 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Laforêt, Fanny
Antoine, Céline
Lebrun, Sarah
Gonza, Irma
Goya-Jorge, Elizabeth
Douny, Caroline
Duprez, Jean-Noël
Scippo, Marie-Louise
Taminiau, Bernard
Daube, Georges
Fall, Abdoulaye
Thiry, Damien
Delcenserie, Véronique
Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model
title Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model
title_full Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model
title_fullStr Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model
title_full_unstemmed Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model
title_short Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model
title_sort impact assessment of vb_kpnp_k1-ulip33 bacteriophage on the human gut microbiota using a dynamic in vitro model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057081/
https://www.ncbi.nlm.nih.gov/pubmed/36992428
http://dx.doi.org/10.3390/v15030719
work_keys_str_mv AT laforetfanny impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT antoineceline impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT lebrunsarah impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT gonzairma impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT goyajorgeelizabeth impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT dounycaroline impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT duprezjeannoel impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT scippomarielouise impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT taminiaubernard impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT daubegeorges impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT fallabdoulaye impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT thirydamien impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel
AT delcenserieveronique impactassessmentofvbkpnpk1ulip33bacteriophageonthehumangutmicrobiotausingadynamicinvitromodel